BioSpace News Archive

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 41,358,603 million units, or 248,516 pounds, of used contact lens, eye and lens care materials.

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the quarter ended September 30, 2021, and provided a corporate update.

Theseus Pharmaceuticals, Inc., a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, announced business and program highlights and reported financial results for the third quarter ended September 30, 2021.

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with the allergy company ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF).

Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH).

PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, announced that new data related to its PACTImmune™ Database were presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting.

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone.

Repare Therapeutics Inc. today announced that members of its senior management team will participate in two virtual investor conferences in November.

Castle Biosciences Named a 2021 Houston Chronicle Top Workplace

Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.